How a viral protein affects HIV persistence in immune cells
Impact of Vpr-induced epigenetic remodeling on HIV persistence
This study is looking at how a specific HIV protein called Vpr helps the virus stay hidden in certain immune cells, and by learning more about this process, researchers hope to find new ways to help people with HIV by getting rid of the virus for good.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project ID | NIH-11187705 on NIH RePORTER |
What this research studies
This research investigates the role of the HIV protein Vpr in maintaining the virus within certain immune cells, particularly myeloid cells. By understanding how Vpr induces changes in the genetic material of these cells, the study aims to uncover new ways to target and eliminate long-lasting HIV reservoirs. The approach involves detailed laboratory experiments to analyze the mechanisms by which Vpr influences HIV persistence, potentially leading to innovative treatment strategies. Patients may benefit from insights that could contribute to the development of a cure for HIV.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV, particularly those with persistent viral reservoirs despite antiretroviral therapy.
Not a fit: Patients who are not infected with HIV or those who have acute HIV infections without established reservoirs may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that effectively eliminate HIV reservoirs, potentially curing patients of the virus.
How similar studies have performed: Previous research has shown promise in targeting viral reservoirs, but the specific approach of studying Vpr's role in myeloid cells is relatively novel.
Where this research is happening
San Antonio, United States
- University of Texas Hlth Science Center — San Antonio, United States (Active)
Researchers
- Principal investigator: Salamango, Daniel James — University of Texas Hlth Science Center
- Study coordinator: Salamango, Daniel James
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.